Pharmafile Logo
Pharmafocus logo
Advanced Search

inflammatory bowel disease

Showing 3 posts of 3 posts found.

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024
Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease

AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …

News

Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment

March 21, 2024
Research and Development Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial

Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …

News

Pfizer invests $25m in Vedanta BioSciences’ IBD treatment

January 13, 2021
Research and Development Pfizer, Vedanta Biosciences, inflammatory bowel disease

Pfizer has invested $25 million in Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases, …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026